Clinical Trial Update: Decitabine for Poor Graft Function Post Allo-HSCT [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating decitabine for poor graft function after allogeneic hematopoietic stem cell transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poor Graft Function

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Poor Graft Function | Phase 3 | Status: NOT_YET_RECRUITING